U.S. Markets closed

Introducing BioDelivery Sciences International (NASDAQ:BDSI), The Stock That Zoomed 197% In The Last Three Years

Simply Wall St

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But if you buy shares in a really great company, you can more than double your money. To wit, the BioDelivery Sciences International, Inc. (NASDAQ:BDSI) share price has flown 197% in the last three years. That sort of return is as solid as granite. Also pleasing for shareholders was the 53% gain in the last three months.

Check out our latest analysis for BioDelivery Sciences International

BioDelivery Sciences International isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Over the last three years BioDelivery Sciences International has grown its revenue at 24% annually. That's well above most pre-profit companies. Along the way, the share price gained 44% per year, a solid pop by our standards. But it does seem like the market is paying attention to strong revenue growth. That's not to say we think the share price is too high. In fact, it might be worth keeping an eye on this one.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

NasdaqGS:BDSI Income Statement, November 6th 2019

Take a more thorough look at BioDelivery Sciences International's financial health with this free report on its balance sheet.

A Different Perspective

It's good to see that BioDelivery Sciences International has rewarded shareholders with a total shareholder return of 50% in the last twelve months. That certainly beats the loss of about 19% per year over the last half decade. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. Before spending more time on BioDelivery Sciences International it might be wise to click here to see if insiders have been buying or selling shares.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.